Puyuan Xing
Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Peking Union Medical College Hospital(CN)National Cancer Center(US)National Clinical Research(US)RE Hydrogen (United Kingdom)(GB)Beijing Information Science & Technology University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer(2017)231 cited
- → Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis(2019)173 cited
- → Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey(2018)133 cited
- → Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial(2019)91 cited
- → Current management of chemotherapy-induced neutropenia in adults: key points and new challenges(2020)87 cited